CoChat

Broadening the Spectrum of β-Lactam Antibiotics through Inhibition of Signal Peptidase Type I

Open access
Therien, Alex G., Huber, Joann L., Wilson, Kenneth E., Beaulieu, Patrick, Caron, Alexandre, Claveau, David, Deschamps, Kathleen, Donald, Robert G. K., Galgoci, Andrew M., Gallant, Michel, Gu, Xin, Kevin, Nancy J., Lafleur, Josiane, Leavitt, Penny S., Lebeau-Jacob, Christian, Lee, Suzy S., Lin, Molly M., Michels, Anna A., Ogawa, Aimie M., Painter, Ronald E., Parish, Craig A., Park, Young-Whan, Benton-Perdomo, Liliana, Petcu, Mihai, Phillips, John W., Powles, Mary Ann, Skorey, Kathryn I., Tam, John, Tan, Christopher M., Young, Katherine, Wong, Simon, Waddell, Sherman T., Miesel, Lynn · 2012 · Antimicrobial Agents and Chemotherapy
Cited by 76

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The resistance of methicillin-resistant Staphylococcus aureus (MRSA) to all β-lactam classes limits treatment options for serious infections involving this organism. Our goal is to discover new agents that restore the activity of β-lactams against MRSA, an approach that has led to the discovery of two classes of natural product antibiotics, a cyclic depsipeptide (krisynomycin) and a lipoglycopeptide (actinocarbasin), which potentiate the activity of imipenem against MRSA strain COL. We report here that these imipenem synergists are inhibitors of the bacterial type I signal peptidase SpsB, a serine protease that is required for the secretion of proteins that are exported through the Sec and Tat systems. A synthetic derivative of actinocarbasin, M131, synergized with imipenem both in vitro and in vivo with potent efficacy. The in vitro activity of M131 extends to clinical isolates of MRSA but not to a methicillin-sensitive strain. Synergy is restricted to β-lactam antibiotics and is not observed with other antibiotic classes. We propose that the SpsB inhibitors synergize with β-lactams by preventing the signal peptidase-mediated secretion of proteins required for β-lactam resistance. Combinations of SpsB inhibitors and β-lactams may expand the utility of these widely prescribed antibiotics to treat MRSA infections, analogous to β-lactamase inhibitors which restored the utility of this antibiotic class for the treatment of resistant Gram-negative infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.00726-12

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 76

Metadata

Authors
Therien, A. G., Huber, J. L., Wilson, K. E., Beaulieu, P., Caron, A., Claveau, D., Deschamps, K., Donald, R. G. K., Galgoci, A. M., Gallant, M., Gu, X., Kevin, N. J., Lafleur, J., Leavitt, P. S., Lebeau-Jacob, C., Lee, S. S., Lin, M. M., Michels, A. A., Ogawa, A. M., Painter, R. E., Parish, C. A., Park, Y.-W., Benton-Perdomo, L., Petcu, M., Phillips, J. W., Powles, M. A., Skorey, K. I., Tam, J., Tan, C. M., Young, K., Wong, S., Waddell, S. T., & Miesel, L.
Venue
Antimicrobial Agents and Chemotherapy
Published
2012-09
Volume
56
Issue
9
Pages
4662-4670
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W1995808283
Cited by
76
References
3
FWCI
4.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Broadening the Spectrum of β-Lactam Antibiotics through Inhibition of Signal Peptidase Type I. https://app.cochat.ai/papers/10.1128/aac.00726-12
The paper
Therien, A. G., Huber, J. L., Wilson, K. E., Beaulieu, P., Caron, A., Claveau, D., Deschamps, K., Donald, R. G. K., Galgoci, A. M., Gallant, M., Gu, X., Kevin, N. J., Lafleur, J., Leavitt, P. S., Lebeau-Jacob, C., Lee, S. S., Lin, M. M., Michels, A. A., Ogawa, A. M., . . . Miesel, L. (2012). Broadening the Spectrum of β-Lactam Antibiotics through Inhibition of Signal Peptidase Type I. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00726-12

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.